Medigen Vaccine Biologics (TWO:6547) — Stock Price

NT$51.90 TWD
▲ 0.58% today

Medigen Vaccine Biologics (TWO:6547) is currently trading at NT$51.90 TWD, up 0.58% today. Over the past 52 weeks, shares have ranged between NT$33.75 and NT$61.00. This page tracks Medigen Vaccine Biologics's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Medigen Vaccine Biologics worth.

Medigen Vaccine Biologics (6547) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Medigen Vaccine Biologics's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.

Medigen Vaccine Biologics Income Statement — Revenue, Profit & Earnings by Year

Medigen Vaccine Biologics's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue NT$613.17 Million NT$605.64 Million NT$389.62 Million NT$365.04 Million NT$3.28 Billion
Cost of Revenue NT$248.50 Million NT$209.22 Million NT$168.48 Million NT$577.64 Million NT$975.96 Million
Gross Profit NT$364.67 Million NT$396.42 Million NT$221.15 Million NT$-212.60 Million NT$2.31 Billion
Research & Development NT$338.57 Million NT$221.51 Million NT$1.19 Billion NT$1.14 Billion NT$1.19 Billion
SG&A NT$291.79 Million NT$320.57 Million NT$86.49 Million NT$110.84 Million NT$140.71 Million
Total Operating Expenses NT$878.86 Million NT$751.30 Million NT$1.43 Billion NT$1.32 Billion NT$1.34 Billion
Operating Income NT$-265.69 Million NT$-145.67 Million NT$-1.21 Billion NT$-1.45 Billion NT$1.42 Billion
EBITDA NT$-1.08 Billion NT$-1.32 Billion NT$1.53 Billion
EBIT NT$-1.21 Billion NT$-1.45 Billion NT$1.42 Billion
Interest Expense NT$8.80 Million NT$18.89 Million NT$37.57 Million NT$26.89 Million NT$6.02 Million
Income Before Tax NT$-281.71 Million NT$-80.47 Million NT$-1.16 Billion NT$-1.47 Billion NT$1.41 Billion
Income Tax Expense NT$1.00 NT$26.89 Million NT$6.02 Million
Net Income NT$-281.71 Million NT$-80.47 Million NT$-1.16 Billion NT$-1.50 Billion NT$1.41 Billion

Medigen Vaccine Biologics Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Medigen Vaccine Biologics's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets NT$3.93 Billion NT$4.36 Billion NT$6.09 Billion NT$7.35 Billion NT$5.30 Billion
Total Current Assets NT$2.36 Billion NT$2.56 Billion NT$4.40 Billion NT$5.46 Billion NT$3.72 Billion
Cash & Equivalents
Short-term Investments NT$1.18 Billion NT$1.20 Billion NT$2.40 Billion NT$3.03 Billion NT$853.10 Million
Net Receivables NT$130.02 Million NT$118.03 Million NT$198.84 Million NT$566.56 Million NT$719.89 Million
Inventory NT$393.75 Million NT$452.06 Million NT$383.63 Million NT$544.78 Million NT$563.50 Million
Property, Plant & Equipment NT$1.47 Billion NT$1.41 Billion
Goodwill
Total Liabilities NT$454.64 Million NT$513.92 Million NT$2.25 Billion NT$2.32 Billion NT$622.95 Million
Total Current Liabilities NT$185.04 Million NT$214.22 Million NT$1.99 Billion NT$355.23 Million NT$439.09 Million
Long-term Debt NT$0.00 NT$1.68 Billion NT$0.00
Net Debt NT$621.54 Million NT$752.31 Million NT$-1.19 Billion
Total Stockholder Equity NT$3.48 Billion NT$3.85 Billion NT$3.85 Billion NT$5.03 Billion NT$4.68 Billion
Retained Earnings NT$-281.71 Million NT$-80.47 Million NT$-1.16 Billion NT$-1.27 Billion NT$1.41 Billion

Medigen Vaccine Biologics Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Medigen Vaccine Biologics generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow NT$-49.09 Million NT$40.75 Million NT$-477.75 Million NT$-1.10 Billion NT$579.89 Million
Capital Expenditures NT$51.78 Million NT$34.98 Million NT$40.95 Million NT$140.34 Million NT$134.97 Million
Free Cash Flow NT$-100.86 Million NT$5.77 Million NT$-518.71 Million NT$-1.24 Billion NT$444.92 Million
Investing Cash Flow NT$-2.40 Billion NT$-930.69 Million
Financing Cash Flow NT$1.01 Million NT$3.32 Billion NT$51.18 Million
Dividends Paid
Stock-Based Compensation NT$31.00 Million NT$14.16 Million NT$18.30 Million NT$75.61 Million NT$68.81 Million
Depreciation NT$141.79 Million NT$136.44 Million NT$131.17 Million NT$127.89 Million NT$112.54 Million
Change in Cash NT$-123.58 Million NT$-677.51 Million NT$173.70 Million NT$-175.44 Million NT$-299.73 Million

Medigen Vaccine Biologics Earnings History — EPS Actual vs. Analyst Estimates

Track Medigen Vaccine Biologics's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 14, 2026 -0.09 0.03 -400.00%
Mar 13, 2026 -0.42 0.09 -566.67%
Nov 13, 2025 -0.07 0.07 -200.00%
Aug 13, 2025 -0.30 0.08 -475.00%
May 15, 2025 -0.06
Mar 05, 2025 -0.06 -0.01 -500.00%
Nov 04, 2024
Mar 08, 2024 -1.77 -0.49 -261.22%